Market Place
Sourcing Support
ENVISION Trial Shows 82.3% Response Duration for UGN-102
28 Oct 2024 //
BUSINESSWIRE
UroGen Announces FDA Acceptance of its NDA for UGN-102
15 Oct 2024 //
BUSINESSWIRE
UroGen Receives Patent For Next-Gen Mitomycin Products
16 Sep 2024 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
06 Jun 2024 //
BUSINESSWIRE
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
03 Jun 2024 //
BUSINESSWIRE
Real-World Analysis: 86% 24-Month RFS With JELMYTO® In Responders
05 May 2024 //
BUSINESSWIRE
UroGen`s ATLAS Shows UGN-102 Durability In Low-Risk NMIBC At AUA
04 May 2024 //
BUSINESSWIRE
UroGen Gets IND For UGN-103 NMIBC Next-Gen Mitomycin
15 Apr 2024 //
BUSINESSWIRE
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
03 Apr 2024 //
BUSINESSWIRE
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation
10 Jul 2023 //
BUSINESSWIRE
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological
20 Jun 2023 //
BUSINESSWIRE
Intas Pharmaceuticals Limited on FDA Import Alert List
06 Jun 2023 //
FDA
New Retrospective Study Presented at AUA 2023 Similar Outcomes Utilizing JELMYTO
30 Apr 2023 //
BUSINESSWIRE
Enforcement Report - Week of January 18, 2023
18 Jan 2023 //
FDA
Results of Post-Commercial Utilization Review of JELMYTO Provide New Evidence
11 Jan 2023 //
BUSINESSWIRE
UroGen Completes Enrollment of PIII Trial for UGN-102 for LG-IR-NMIBC
19 Dec 2022 //
BUSINESSWIRE
UroGen Pharma to Host Thought Leader Webinar on UGN-102
11 Oct 2022 //
BUSINESSWIRE
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO
28 Sep 2022 //
BUSINESSWIRE
Hong Kong`s Generic Mitomycin Receives Approval in the U.S.
06 Sep 2022 //
FDA
UroGen Pharma Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2022 //
BUSINESSWIRE
UroGen`s Data Shows In-Office Nephrostomy Tube Administration of Jelmyto
10 Feb 2022 //
BUSINESSWIRE
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102 in NMIBC
03 Feb 2022 //
BUSINESSWIRE
UroGen Pharma’s Publishes Phase 2b Study of UGN-102 in LG IR-NMIBC
05 Oct 2021 //
BUSINESSWIRE
UroGen Pharma Presents Novel Clinical Data at 2021 AUA Annual Meeting
13 Sep 2021 //
BUSINESSWIRE
The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
30 Apr 2020 //
BUSINESSWIRE
FDA Approves First Therapy for Treatment of Low-Grade Upper
15 Apr 2020 //
FDA
FDA Approves First Therapy for of Low-Grade Upper Tract Urothelial Cancer
15 Apr 2020 //
PR NEWSWIRE
UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102
03 Apr 2020 //
BUSINESSWIRE
Enforcement Report - Week of August 14, 2019
14 Aug 2019 //
FDA
Common Cold Virus Might Be Effective in Treating Bladder and Other Cancers
08 Jul 2019 //
BIOSPACE
Leiters, Mobius Therapeutics Enter National Sales Agreement Mitosol®
14 Feb 2019 //
PR NEWSWIRE
Mylan Adds to Growing Oncology Portfolio with Generic Mutamycin® Inj
20 Mar 2018 //
PRNEWSWIRE
Enforcement Report - Week of February 7, 2018
07 Feb 2018 //
FDA
Enforcement Report - Week of January 24, 2018
24 Jan 2018 //
FDA
Mylan Lab`s Generic Mitomycin Receives Approval In US
20 Oct 2017 //
FDA
Prescription-drug supply shortages fuel price hikes, new research shows
17 Apr 2017 //
FIERCE PHARMA
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection
19 Sep 2016 //
EDQM
Broken Market for Old Drugs Means Price Spikes Are Here to Stay
18 Nov 2015 //
BLOOMBERG
